• Something wrong with this record ?

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

AS. Kazerouni, LM. Peterson, I. Jenkins, A. Novakova-Jiresova, HM. Linden, JR. Gralow, DM. Hockenbery, DA. Mankoff, PL. Porter, SC. Partridge, JM. Specht

. 2023 ; 25 (1) : 138. [pub] 20231109

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural

Persistent link   https://www.medvik.cz/link/bmc24000709

Grant support
R01 CA248192 NCI NIH HHS - United States
P50 CA138293 NCI NIH HHS - United States
P30 CA015704 NCI NIH HHS - United States

PURPOSE: To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer. METHODS: Patients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre, mid, and post-NAC), prior to surgery. Imaging included diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI and quantitative 18F-FDG PET. Tumor imaging measures included apparent diffusion coefficient, peak percent enhancement (PE), peak signal enhancement ratio (SER), functional tumor volume, and washout volume on MRI and standardized uptake value (SUVmax), glucose delivery (K1) and FDG metabolic rate (MRFDG) on PET, with percentage changes from baseline calculated at mid- and post-NAC. Associations of imaging measures with pathological response (residual cancer burden [RCB] 0/I vs. II/III) and RFS were evaluated. RESULTS: Thirty-five patients with stage II/III invasive breast cancer were enrolled in the prospective study (median age: 43, range: 31-66 years, RCB 0/I: N = 11/35, 31%). Baseline imaging metrics were not significantly associated with pathologic response or RFS (p > 0.05). Greater mid-treatment decreases in peak PE, along with greater post-treatment decreases in several DCE-MRI and 18F-FDG PET measures were associated with RCB 0/I after NAC (p < 0.05). Additionally, greater mid- and post-treatment decreases in DCE-MRI (peak SER, washout volume) and 18F-FDG PET (K1) were predictive of prolonged RFS. Mid-treatment decreases in metabolism/perfusion ratios (MRFDG/peak PE, MRFDG/peak SER) were associated with improved RFS. CONCLUSION: Mid-treatment changes in both PET and MRI measures were predictive of RCB status and RFS following NAC. Specifically, our results indicate a complementary relationship between DCE-MRI and 18F-FDG PET metrics and potential value of metabolism/perfusion mismatch as a marker of patient outcome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000709
003      
CZ-PrNML
005      
20240213093328.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13058-023-01722-4 $2 doi
035    __
$a (PubMed)37946201
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kazerouni, Anum S $u Department of Radiology, University of Washington/Fred Hutchinson Cancer Center, Seattle, WA, USA
245    10
$a Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer / $c AS. Kazerouni, LM. Peterson, I. Jenkins, A. Novakova-Jiresova, HM. Linden, JR. Gralow, DM. Hockenbery, DA. Mankoff, PL. Porter, SC. Partridge, JM. Specht
520    9_
$a PURPOSE: To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer. METHODS: Patients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre, mid, and post-NAC), prior to surgery. Imaging included diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI and quantitative 18F-FDG PET. Tumor imaging measures included apparent diffusion coefficient, peak percent enhancement (PE), peak signal enhancement ratio (SER), functional tumor volume, and washout volume on MRI and standardized uptake value (SUVmax), glucose delivery (K1) and FDG metabolic rate (MRFDG) on PET, with percentage changes from baseline calculated at mid- and post-NAC. Associations of imaging measures with pathological response (residual cancer burden [RCB] 0/I vs. II/III) and RFS were evaluated. RESULTS: Thirty-five patients with stage II/III invasive breast cancer were enrolled in the prospective study (median age: 43, range: 31-66 years, RCB 0/I: N = 11/35, 31%). Baseline imaging metrics were not significantly associated with pathologic response or RFS (p > 0.05). Greater mid-treatment decreases in peak PE, along with greater post-treatment decreases in several DCE-MRI and 18F-FDG PET measures were associated with RCB 0/I after NAC (p < 0.05). Additionally, greater mid- and post-treatment decreases in DCE-MRI (peak SER, washout volume) and 18F-FDG PET (K1) were predictive of prolonged RFS. Mid-treatment decreases in metabolism/perfusion ratios (MRFDG/peak PE, MRFDG/peak SER) were associated with improved RFS. CONCLUSION: Mid-treatment changes in both PET and MRI measures were predictive of RCB status and RFS following NAC. Specifically, our results indicate a complementary relationship between DCE-MRI and 18F-FDG PET metrics and potential value of metabolism/perfusion mismatch as a marker of patient outcome.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    12
$a nádory prsu $x diagnostické zobrazování $x farmakoterapie $7 D001943
650    _2
$a fluorodeoxyglukosa F18 $x terapeutické užití $7 D019788
650    _2
$a neoadjuvantní terapie $x metody $7 D020360
650    _2
$a radiofarmaka $x terapeutické užití $7 D019275
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a pozitronová emisní tomografie $x metody $7 D049268
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Peterson, Lanell M $u Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1144 Eastlake (Mail Stop LG-500), Seattle, WA, 98109-1023, USA
700    1_
$a Jenkins, Isaac $u Fred Hutchinson Cancer Consortium, Seattle, WA, USA
700    1_
$a Novakova-Jiresova, Alena $u Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Linden, Hannah M $u Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1144 Eastlake (Mail Stop LG-500), Seattle, WA, 98109-1023, USA
700    1_
$a Gralow, Julie R $u American Society of Clinical Oncology, Alexandria, VA, USA
700    1_
$a Hockenbery, David M $u Fred Hutchinson Cancer Consortium, Seattle, WA, USA
700    1_
$a Mankoff, David A $u Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Porter, Peggy L $u Fred Hutchinson Cancer Consortium, Seattle, WA, USA
700    1_
$a Partridge, Savannah C $u Department of Radiology, University of Washington/Fred Hutchinson Cancer Center, Seattle, WA, USA
700    1_
$a Specht, Jennifer M $u Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1144 Eastlake (Mail Stop LG-500), Seattle, WA, 98109-1023, USA. jspecht@uw.edu
773    0_
$w MED00006602 $t Breast cancer research $x 1465-542X $g Roč. 25, č. 1 (2023), s. 138
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37946201 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093326 $b ABA008
999    __
$a ok $b bmc $g 2049374 $s 1210403
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 1 $d 138 $e 20231109 $i 1465-542X $m Breast cancer research $n Breast Cancer Res $x MED00006602
GRA    __
$a R01 CA248192 $p NCI NIH HHS $2 United States
GRA    __
$a P50 CA138293 $p NCI NIH HHS $2 United States
GRA    __
$a P30 CA015704 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options